Groupama Asset Managment bought a new position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 600,000 shares of the company's stock, valued at approximately $17,700,000. Groupama Asset Managment owned approximately 1.20% of Immunocore as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Immunocore by 0.5% in the 3rd quarter. FMR LLC now owns 4,836,040 shares of the company's stock worth $150,546,000 after buying an additional 23,436 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Immunocore by 7,437.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company's stock worth $2,872,000 after buying an additional 91,033 shares during the last quarter. Verition Fund Management LLC purchased a new stake in Immunocore in the third quarter worth approximately $739,000. State Street Corp grew its position in Immunocore by 63.9% during the third quarter. State Street Corp now owns 76,671 shares of the company's stock valued at $2,387,000 after acquiring an additional 29,897 shares during the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of Immunocore by 65.6% during the third quarter. Two Sigma Advisers LP now owns 757,700 shares of the company's stock worth $23,587,000 after acquiring an additional 300,200 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on IMCR shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a research note on Wednesday, March 12th. Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Immunocore presently has a consensus rating of "Moderate Buy" and a consensus price target of $65.64.
Check Out Our Latest Research Report on IMCR
Insider Buying and Selling
In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the company's stock in a transaction dated Monday, March 17th. The shares were purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the transaction, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. This trade represents a 60.40 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.10% of the stock is owned by insiders.
Immunocore Trading Down 6.1 %
IMCR stock traded down $1.78 during trading on Friday, reaching $27.26. The company had a trading volume of 291,844 shares, compared to its average volume of 443,178. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore Holdings plc has a 52 week low of $27.19 and a 52 week high of $64.10. The business has a 50 day moving average of $29.80 and a 200 day moving average of $30.82. The company has a market cap of $1.36 billion, a P/E ratio of -28.69 and a beta of 0.75.
About Immunocore
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Featured Articles
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
